EPSTI1 as an immune biomarker predicts the prognosis of patients with stage III colon cancer.

Front Immunol · 2022 · PMC9623419 · PMID 36330510

Europe PMC DOI

hedged sentence

0.0760

closest p · 1.5× alpha

0.0760

boldest claim

The sentences

only marginally significantP = 0.076so close (0.05 < p ≤ 0.1)

In the GSE39582 cohort, the difference was only marginally significant ( Figure 5B ; P = 0.076), although the high EPSTI1 group still had a smaller infiltration abundance than the low EPSTI1 group.

also in 5,076 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.